GB 1275
Alternative Names: GB-1275; ONT-01Latest Information Update: 27 May 2026
At a glance
- Originator Adhaere Pharmaceuticals
- Developer Allosite Therapeutics; Gossamer Bio
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action CD11b antigen agonists
-
Orphan Drug Status
Yes - Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Focal segmental glomerulosclerosis; Solid tumours
- Phase 0 Lupus nephritis; Systemic lupus erythematosus
Most Recent Events
- 27 May 2026 Phase-I clinical trials in Focal segmental glomerulosclerosis (PO) (Allosite Therapeutics pipeline, April 2026)
- 01 Apr 2026 Allosite Therapeutics completes phase-I clinical trials in Solid tumours (PO) (Allosite Therapeutics pipeline, April 2026)
- 20 Nov 2025 Phase-0 for Lupus nephritis in USA (PO) (NCT07107659)